/
•
•
Context is everything.
Detailed stories on technology startups, business and economic current affairs.
Detailed stories on technology startups, business and economic current affairs.
The Hyderabad-based generics maker has seen its stock scale all-time highs and lows in quick succession. With big plans in place and regulatory heat easing, its roller-coaster days may be over.
To borrow from Winston Churchill, Aurobindo Pharma is a riddle, wrapped in a mystery, inside an enigma.
Back in August 2020, the Hyderabad-based company’s stock hit a 10-year high after it dethroned Sun Pharma as the top pharmaceuticals supplier to the lucrative US market. The 2020-21 fiscal was its best ever in terms of profits—at Rs 5,344 crore. We wrote about it here.
At that point, it seemed Aurobindo Pharma couldn’t put a foot wrong. Except it did.
A lot of its good tidings had to do with the US Food and Drug Administration largely clearing it of wrongdoing …
